Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
Fate Therapeutics
(NQ:
FATE
)
2.380
-0.180 (-7.03%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 12, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Fate Therapeutics
< Previous
1
2
3
4
5
6
7
8
9
Next >
Fate Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates
February 28, 2023
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
FATE NOTICE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Fate Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - FATE
February 28, 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Fate, Sotera, Argo, and National Vision and Encourages Investors to Contact the Firm
February 24, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
Analyst Ratings for Fate Therapeutics
January 24, 2023
Via
Benzinga
ROSEN, A GLOBAL AND LEADING FIRM, Encourages Fate Therapeutics, Inc. Investors with Loses to Secure Counsel Before Important Deadline in Securities Class Action - FATE
February 21, 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against IBM, Fate, Sotera, and Argo and Encourages Investors to Contact the Firm
February 19, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
ROSEN, A RANKED AND LEADING FIRM, Encourages Fate Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - FATE
February 16, 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Fate Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline – FATE
February 14, 2023
From
Pomerantz LLP
Via
GlobeNewswire
Outset Medical, SolarEdge Technologies And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
February 14, 2023
Don’t forget to check out our premarket coverage here Fate Therapeutics, Inc. (NASDAQ: FATE) fell 4.1% to $6.13 in pre-market trading. Fate Therapeutics is expected to report Q4 results on Tuesday,...
Via
Benzinga
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Fate, Sotera, Argo, and National Vision and Encourages Investors to Contact the Firm
February 13, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2022 Financial Results
February 13, 2023
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Sorrento Therapeutics, Citius Pharmaceuticals And Other Big Stocks Moving Lower In Monday's Pre-Market Session
February 13, 2023
U.S. stock futures traded slightly higher this morning. Here are some big stocks recording losses in today’s pre-market trading session.
Via
Benzinga
ROSEN, A RESPECTED AND LEADING FIRM, Encourages Fate Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - FATE
February 10, 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Bioventus, ESS, IBM, and FATE and Encourages Investors to Contact the Firm
February 08, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
ROSEN, LEADING INVESTOR COUNSEL, Encourages Fate Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - FATE
February 07, 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Bioventus, ESS, IBM, and FATE and Encourages Investors to Contact the Firm
February 03, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
Fate Therapeutics, Inc. (FATE) Shareholder Notice: Robbins LLP Reminds Investors of Lead Plaintiff Deadline in Class Action Against Fate Therapeutics, Inc.
February 02, 2023
From
Robbins LLP
Via
Business Wire
Kirby McInerney LLP Reminds Investors That a Class Action Lawsuit Has Been Filed on Behalf of Fate Therapeutics, Inc. (FATE) Investors and Encourages Investors to Contact the Firm Before March 22, 2023
February 01, 2023
From
Kirby McInerney LLP
Via
Business Wire
ROSEN, A TOP RANKED LAW FIRM, Encourages Fate Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - FATE
February 01, 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
Fate Therapeutics, Inc. (NASDAQ: FATE) Investor Notice: Lawsuit Alleges Securities Laws Violations
January 31, 2023
San Diego, CA -- (SBWIRE) -- 01/31/2023 -- An investor, who purchased NASDAQ: FATE shares, filed a lawsuit against Fate Therapeutics, Inc over alleged violations of Federal Securities Laws.
Via
SBWire
NOTICE: Investors in Fate Therapeutics, Inc. with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – FATE
January 30, 2023
From
Robbins Geller Rudman & Dowd LLP
Via
Business Wire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against FATE, and Sotera and Encourages Investors to Contact the Firm
January 29, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Fate Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - FATE
January 29, 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
5 Cheapest Health Care Stocks You Should Think About
January 27, 2023
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Via
Benzinga
ROSEN, LEADING INVESTOR COUNSEL, Encourages Fate Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - FATE
January 26, 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Fate Therapeutics, Inc. (FATE)
January 26, 2023
From
Glancy Prongay & Murray LLP
Via
Business Wire
Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Fate Therapeutics, Inc. (FATE)
January 25, 2023
From
Law Offices of Howard G. Smith
Via
Business Wire
INVESTOR NOTICE: Fate Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead the Fate Therapeutics Class Action Lawsuit – FATE
January 25, 2023
From
Robbins Geller Rudman & Dowd LLP
Via
Business Wire
How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
January 25, 2023
Five biotechs have already issued layoffs in 2023. Many seem to have good potential, but time will tell if the shifts create the value analysts anticipate.
Via
MarketBeat
Topics
Workforce
Exposures
Layoff
Product Safety
Shareholder Alert: Robbins LLP Informs Investors of Class Action Against Fate Therapeutics, Inc. (FATE)
January 24, 2023
From
Robbins LLP
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.